Crossmark

Co-targeting PLK1 and mTOR induces synergistic inhibitory effects against esophageal squamous cell carcinoma

Crossref DOI link: https://doi.org/10.1007/s00109-018-1663-4

Published Online: 2018-06-29

Published Print: 2018-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Liu, Ting-Ting

Yang, Kai-Xia

Yu, Jing

Cao, Ying-Ya

Ren, Jian-Song

Hao, Jia-Jie

Pan, Bei-Qing

Ma, Sai

Yang, Li-Yan

Cai, Yan

Wang, Ming-Rong

Zhang, Yu https://orcid.org/0000-0003-1375-1594
Funding

Funding for this research was provided by:

Beijing Municipal Natural Science Foundation (CN) (7151008)

National Natural Science Foundation of China (81330052)

National Natural Science Foundation of China (81520108023)

CAMS Innovation Fund for Medical Sciences (CIFMS) (2016-I2M-3-007)
License Information

Text and Data Mining valid from 2018-06-29
More Information

Article History

Received: 12 January 2018

Revised: 13 June 2018

Accepted: 19 June 2018

First Online: 29 June 2018

Compliance with ethical standards

: Animal protocols were approved by the Animal Center of National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC).

: The authors declare that they have no conflict of interest.